This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Nonetheless, Moderna has previously been involved in licensing deals to advance its technology. The data was from their phase 2b trial of a personalised vaccine consisting of 34 mRNAs, each targeting mutations – identified by genesequencing – thought to be driving a patient’s cancer.
It has already filed a rolling license application in Canada, and has also picked up fast-track status for the shot from the US FDA. If the data are positive, the company could be looking at emergency approvals in the latter half of the year.
It may also use the cash injection for “in-licensing opportunities and potential acquisitions”, according to the document. The post Oxford Nanopore makes stellar debut on UK stock market appeared first on.
As per the company, dbDNA is suitable for rapid, scalable manufacture of GMP DNA and can incorporate genesequences of sizes ranging from 500bp to 20kb, which are typically unstable as pDNA. Biopharmaceutical companies like Pfizer and Lonza have announced licensing agreements to use the doggybone in their own respective research.
In November 2019 it was licensed for use by the European Medicines Agency and is now prequalified by WHO, the US FDA, as well as in eight African countries. This is a priority area for us to ensure that all African countries are equipped to carry out genesequencing locally or can send samples to reference laboratories.”.
Rather, developers of diagnostic tests and, indeed of any product that relies on free access to genesequence and other biomarker information, should pay also close attention, as PERA would overturn longstanding judicial precedent. The concerns raised by PERA are not limited to these industries, however.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content